China’s First HIV Vaccine Enters Phase II Clinical Trials

SHANGHAI - China's State FDA approved an application March 23 for an HIV vaccine funded by the Chinese government and developed by Jilin University to proceed to Phase II clinical trials. The trials will enroll 230 healthy people with high risk of HIV infection. The vaccine targets an HIV subtype that was detected in Chinese patients